Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Herbal supplement could help smokers quit: A wild oats extract that Frutarom Switzerland developed for its Neuravena herbal supplement potentially could help smokers quit if used in the first few weeks after stopping smoking, according research in Japan. A recent study in Pharmocometrics found the eight participants cut the number of cigarettes they smoked daily to between 4.5 and 13.3 from 15.9 to 23.1 by taking three capsules of Neuravena daily for 28 days. The average carbon monoxide concentration the men exhaled also fell from a median level of 17 ppm to 11.9 ppm. The researchers say the CO concentration drop was not statistically significant, and mental stress levels did not change. They suggest future studies examine Neuravena's effect for a longer period and with different intake amounts. The study, conducted by researchers including staff from ASK Intercity Co., which distributes Neuravena, was not blinded or placebo controlled

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS102828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel